Objective: To analyze the clinical characteristics of bone loss in hospitalized patients with Graves’ disease. Methods: The clinical data of hospitalized patients with Graves’ disease were collected. According to the results of bone density examinations, they were divided into a normal bone density group, a low bone mass group, and an osteoporosis group. The normal bone density group was used as the control group to analyze the clinical characteristics of bone loss. Results: The incidence of bone loss in patients with Graves’ disease was 80.72%, with osteoporosis accounting for 39.16% and low bone mass accounting for 41.57%. The incidences of hyperthyroid heart disease, Graves’ ophthalmopathy, and leukopenia in the osteoporosis group and the low bone mass group were significantly higher than those in the normal bone density group, reaching 84.62%, 60.87%, and 34.38%, respectively (P < 0.05). The age of the osteoporosis group with Graves’ disease was 50.88 ± 12.03 years old, which was higher than that of the normal bone density group (40.03 ± 12.58 years old). The disease course was 55.66 ± 14.21 days, longer than that of the normal bone density group (43.38 ± 8.55 days). FT4 was 61.69 ± 8.42 pmol/L, higher than that of the normal bone density group (51.01 ± 6.77 pmol/L), while TSH was 0.08 ± 0.51 μIU/ml, lower than that of the normal bone density group (0.22 ± 0.55 μIU/ml). The blood phosphorus was 1.25 ± 0.29 mmol/L, lower than that of the normal bone density group (1.34 ± 0.27 mmol/L), with statistical significance (P < 0.05). In the low bone mass group, FT3 (13.08 ± 9.05 pmol/L) and FT4 (46.14 ± 3.46 pmol/L) were lower than those in the normal bone density group, with statistical significance (P < 0.05). Logistic regression analysis revealed that age, disease course, and TSH were contributing factors to bone loss. Conclusion: Patients with Graves’ disease are prone to bone loss, and age, disease course, and TSH are contributing factors to bone loss.